France's health minister wants to limit use of a popular malaria drug as a coronavirus treatment after a new study found it ineffective and warned of increased health risks.
Olivier Veran tweeted Saturday that he asked France's public health council to draft new rules for prescribing hydroxychloroquine and other treatments within 48 hours.
He specifically cited a study of 100,000 patients worldwide, published Friday in the Lancet, saying hydroxychloroquine and related drug chloroquine were ineffective against the virus and were tied to a greater risk of death and heart rhythm problems.
Prominent French virologist Dr. Didier Raoult drew international attention including from U.S. President Donald Trump for his research early in the pandemic suggesting hydroxychloroquine reduced virus symptoms. Raoult's office didn't comment on the minister's move.
France included the drug in a trial of multiple treatments and allowed its use for hospitalized patients.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.